Menopause: Why the Hormones Fall and What Changes
Menopause is not a switch that flips. It is two stories running at once: an ovary quietly running out of follicles, and a brain that keeps shouting louder and louder into an emptying room. Press play and watch the follicle pool drain, the FSH signal climb, and estradiol go from a smooth monthly wave to a rollercoaster to a flat line — then watch what that does to a thermostat and to a piece of bone.
Try this: start on Reproductive and press 🌡️ Trigger a hot flash. Almost nothing happens. Now switch to Postmenopause and press it again. Identical heat load, completely different result — because the thermoneutral zone has narrowed from about 0.4 °C to almost nothing.
Live hormone readout
What’s happening
What is real and what is modelled. The numbers in the readout are real clinical reference values: estradiol cycling roughly 30–400 pg/mL in the reproductive years and typically under 20–30 pg/mL after menopause; FSH under about 10 IU/L premenopausally and commonly above 25–40 IU/L afterwards; AMH falling to undetectable; spine bone loss of roughly 2% a year in the couple of years around the final period, as measured in the Study of Women’s Health Across the Nation (SWAN). The curves themselves are an illustrative model, not plotted patient data — they are generated by equations chosen to reproduce the published shape and range, and the perimenopausal variability is deliberately randomised, so no two runs look the same. The follicle dots are a representative sample, not one dot per follicle: a real ovary holds tens of thousands of them at 35 and roughly a thousand at menopause. Hot-flash frequency is a modelled estimate.
The Science in Plain Language
Menopause is a diagnosis you can only make looking backwards
Menopause is a single day, and you can only identify it a year after it happens. The definition is twelve consecutive months without a menstrual period, with no other explanation. That last period is called the final menstrual period — the FMP marked in yellow on the timeline above. Everything before it is perimenopause; everything after is postmenopause. In industrialised countries the median age at natural menopause is about 51, with a normal range of roughly 45 to 55. Before 45 it is called early menopause; before 40 it is primary ovarian insufficiency, which is a different clinical situation and needs a different conversation.
That retrospective definition has an awkward consequence, and it is worth naming plainly: for the several years when symptoms are usually at their worst, there is no test that can tell you where you are. You are diagnosed by what has already stopped happening. The STRAW+10 staging system, which is what specialists actually use, gets around this by staging you on your bleeding pattern rather than your bloodwork — a persistent difference of seven days or more between consecutive cycle lengths marks the early transition, and a stretch of sixty days or more without bleeding marks the late transition.
The ovary is running out of follicles — and it has been all along
You are born with every egg you will ever have. A female fetus holds somewhere around six to seven million primordial follicles at about twenty weeks of gestation; roughly one to two million remain at birth; a few hundred thousand at puberty. From then on they are lost continuously, and only about four hundred are ever ovulated. The rest disappear through atresia — programmed follicular death that runs quietly in the background every single day, whether you are pregnant, on the pill, or ovulating normally.
By the mid-thirties there may be tens of thousands left. By the final menstrual period, roughly a thousand. That is what the left panel is showing you: the dots drain away, and everything else on the page is downstream of that one fact.
The first hormonal sign is not estradiol. It is inhibin B, made by the small growing follicles, whose job is to selectively suppress FSH. As the pool of small follicles shrinks, inhibin B falls — and FSH, released from that restraint, starts to creep up years before anyone notices a symptom. Anti-Müllerian hormone (AMH) tracks the same pool and falls in parallel; it becomes effectively undetectable a few years before the final period. Estradiol, notably, holds up for a surprisingly long time, because the rising FSH whips the remaining follicles harder. That is the mechanism behind the single most misunderstood part of this whole process.
Why perimenopause often feels worse than menopause itself
The popular picture is a smooth ramp downwards. It is nothing like that. Switch the animation to Perimenopause and watch the pink curve: it does not slide, it lurches. Some cycles produce estradiol peaks higher than a normal reproductive cycle, because a pituitary shouting FSH at a thinning follicle pool sometimes recruits several follicles at once. Other cycles are anovulatory — a follicle grows partway, never releases, and there is no luteal phase and no progesterone behind it.
So the perimenopausal complaint list — breast tenderness, heavier or unpredictable bleeding, migraine, mood swings, sleep that shatters at 3 a.m. — is not a list of low-estrogen symptoms. Much of it is the symptom profile of erratic and sometimes high estradiol arriving without the steadying progesterone that follows ovulation. It is the volatility, not the level, that hurts. This is also why women are so often told their bloodwork is “normal”: on the day of the draw, it frequently is.
The transition is not brief. The menopausal transition typically lasts about four years, and the whole span from the first cycle irregularity to settled postmenopause can run seven to ten. SWAN found the median total duration of hot flashes and night sweats to be 7.4 years — and for women whose symptoms started while they were still cycling regularly, longer still. Anyone who was told to expect “a bad year or two” was misinformed.
A hot flash is a thermostat problem, not a hormone problem
This is the part the animation was built for. Your hypothalamus defends core body temperature within a narrow band: warm above the upper edge and you sweat and dilate skin vessels; cool below the lower edge and you shiver and constrict them. Between the two edges you do neither. That band is the thermoneutral zone, and in a comfortable person it is roughly 0.4 °C wide.
In women with frequent hot flashes, that band collapses to nearly nothing. The classic thermoregulatory work by Robert Freedman found the zone essentially reduced to near zero in symptomatic women, versus about 0.4 °C in asymptomatic ones. Core temperature normally drifts up and down by small fractions of a degree all day long, and you never notice. Narrow the zone and those same ordinary drifts now punch straight through the sweating threshold. The result is the full heat-dissipation response fired at maximum for a body that was not actually overheated: skin blood flow surges, sweating starts, and then — because you just dumped real heat — core temperature overshoots downwards and you get the chill that so many women describe and few doctors ask about.
Press Trigger a hot flash in each scenario and you can see this directly. The button applies the same small heat load every time. In the reproductive scenario the zone swallows it. Postmenopausally, the same load fires a flash.
Why does the zone narrow? Estrogen withdrawal remodels a specific group of neurons in the hypothalamic infundibular nucleus — the KNDy neurons, named for the three signals they co-express: kisspeptin, neurokinin B, and dynorphin. Normally estrogen restrains them. Take estrogen away and they hypertrophy and fire harder, and their neurokinin B signalling — acting through the NK3 receptor — reaches into the neighbouring median preoptic area, which is the thermoregulatory control centre. That is the anatomical link between an empty ovary and a soaked nightdress.
It is also a drug target, and the drug exists. Fezolinetant is a selective NK3-receptor antagonist approved for moderate-to-severe vasomotor symptoms of menopause — the first non-hormonal treatment designed from this mechanism rather than discovered by accident. In its phase 3 SKYLIGHT trials it reduced hot-flash frequency and severity substantially compared with placebo. It is not free of considerations: the label requires liver-function testing before starting and periodically afterwards, following reports of rare but serious liver injury. A second drug in the class, elinzanetant, blocks both the NK-1 and NK-3 receptors. Toggle NK3 blocker in the animation and watch the green band widen — and note what does not change: the bone panel. Blocking NK3 treats the thermostat. It does nothing for the skeleton.
Why bone loss accelerates — estrogen was holding the osteoclasts back
Bone is not inert. It is continuously demolished and rebuilt by two cell teams: osteoclasts that resorb old bone and osteoblasts that lay down new. The pace and balance of that turnover is set largely by a signalling pair, RANKL and its decoy receptor OPG. RANKL recruits and activates osteoclasts and keeps them alive; OPG mops RANKL up before it can.
Estrogen is one of the main brakes on this system. It suppresses RANKL, raises OPG, and shortens osteoclast lifespan. Remove estrogen and the RANKL/OPG ratio climbs, osteoclasts become more numerous and longer-lived, the remodelling cycle speeds up, and demolition outruns rebuilding. Watch the RANKL/OPG bar in the bone panel move as you switch scenarios.
The timing is sharp, and it is one of the most clinically useful facts on this page. Bone loss is not a slow steady drip from your forties. SWAN measured it directly across the transition and found the fastest loss in a window running from about a year before the final period to two years after it, at roughly 2% a year at the spine and around 1% a year at the hip. Women lose on the order of 10% of their bone mass in the decade surrounding menopause. Structurally, the damage is not only thinning: once a trabecular strut is perforated and lost, it is gone, and the neighbouring struts inherit its load. That is why the animation shows struts disappearing and not coming back — adding bone density later does not rebuild lost architecture.
The Resistance + Ca/D toggle models what the non-drug side genuinely does. Resistance and impact training plus adequate calcium and vitamin D meaningfully slows the rate; it does not abolish it, and the animation is honest about that. If you want the underlying machinery in detail, the bone remodelling animation and the calcium and PTH animation show it cell by cell. As an aside that ties the whole mechanism together: the osteoporosis drug denosumab is a monoclonal antibody against RANKL. It works by doing artificially what estrogen used to do naturally.
Genitourinary syndrome of menopause — and why local estrogen is a different drug
Hot flashes get the attention; this gets the silence. The vulva, vagina, urethra and bladder trigone are densely populated with estrogen receptors. As estradiol falls, the vaginal epithelium thins and loses glycogen, blood flow and lubrication drop, elasticity declines, and the vaginal pH rises from an acidic premenopausal range toward neutral, which shifts the resident microbiome away from lactobacilli. The result is dryness, burning, painful sex, urinary urgency and recurrent urinary tract infections. The umbrella term is genitourinary syndrome of menopause (GSM).
Two things separate GSM from vasomotor symptoms, and both matter. First, hot flashes eventually burn out on their own; GSM does not. It is progressive and it persists indefinitely without treatment. Second — and this is the point most often lost — low-dose vaginal estrogen is not systemic hormone therapy in a different bottle. It is dosed in micrograms rather than milligrams, applied where the receptors are, and absorbed so little that serum estradiol generally stays within the postmenopausal range. Professional guidance reflects that difference: low-dose vaginal estrogen is not considered to require an added progestogen for endometrial protection in a woman with a uterus, whereas systemic estrogen is. Treating a systemic-therapy risk discussion as though it automatically applies to a vaginal tablet is a category error, and it leaves a lot of women untreated for something eminently treatable. Non-hormonal vaginal moisturisers and lubricants are a reasonable first step, and for some women they are enough.
What blood tests can and cannot tell you
The single most common request in perimenopause is “can you just test my hormones?”, and the honest answer is that in perimenopause the tests are usually not the tool you want.
Run the animation on Perimenopause and watch the FSH curve bounce. That is the problem in one picture. FSH swings from near-premenopausal to postmenopausal values and back again, sometimes within the same month, so a single value tells you what was happening on the morning of the draw and very little else. A high FSH does not prove you are done cycling — spontaneous ovulation and pregnancy after a postmenopausal-range FSH are documented. A normal FSH does not prove you are not in transition. Estradiol has the same problem for the same reason.
What the tests are good for: FSH and estradiol are genuinely diagnostic under 40, where the question is primary ovarian insufficiency and the answer changes management substantially. Thyroid function is worth checking because hypothyroidism impersonates perimenopause convincingly. AMH reflects the size of the remaining follicle pool and is useful in fertility planning, but it cannot predict your date of menopause with any precision for an individual, and it should not be sold as though it can. Note in the animation that AMH stays flat and undetectable on the HRT scenario: hormone therapy relieves symptoms, it does not restore the ovary, and it does not change AMH.
For a woman over 45 with typical symptoms and changing cycles, guidelines are consistent: the diagnosis is clinical. Ask for tests to exclude something else, not to confirm the obvious. Related lab background is on our lab tests pages.
The myth: “the WHI proved hormone therapy is dangerous”
In July 2002 the estrogen-plus-progestin arm of the Women’s Health Initiative was stopped early and the finding was announced at a press conference before most clinicians had read the paper. The headline was breast cancer and heart disease. Within a year, hormone-therapy prescribing had collapsed, and it has never returned to anything close to its former level. A generation of women stopped treatment, and a generation of doctors trained afterwards learned to be afraid of it. Here is what the trial actually found, and what has been learned since.
The results were reported as relative risks, which sound alarming and convey nothing about how likely something is to happen to you. In absolute terms, over one year in the estrogen-plus-progestin arm, per 10,000 women, there were about 8 more cases of invasive breast cancer, 7 more coronary heart disease events, 8 more strokes and 8 more pulmonary emboli — alongside about 5 fewer hip fractures and 6 fewer colorectal cancers. Those are real harms and they should not be waved away. They are also small numbers, and the benefit column was reported far less often than the harm column.
Three further points changed the interpretation. First, the WHI enrolled women at an average age of 63, more than a decade past a typical menopause, and only a small minority were in their fifties — yet the results were applied to 51-year-olds with hot flashes, who were not the population studied. Second, the trial had a second arm: women who had had a hysterectomy took estrogen alone, without a progestin, and that arm showed no increase in breast cancer — the signal, in fact, pointed the other way. The breast-cancer headline came overwhelmingly from the combined arm, but the public message did not preserve that distinction. Third, later age-stratified analyses of the WHI itself, together with the KEEPS and ELITE trials, gave rise to the timing hypothesis: that the cardiovascular effect of estrogen depends on when it is started, being potentially neutral or favourable in arteries that are still relatively healthy and unfavourable in arteries with established plaque. ELITE, which was designed specifically to test this, found slowing of carotid artery wall thickening in women who started estradiol within six years of menopause but not in those who started ten or more years out.
The professional position that emerged is materially different from the 2002 headline. Major menopause societies now hold that for women who are under 60 or within 10 years of their final period, and who do not have specific contraindications, the benefit-risk profile of systemic hormone therapy for bothersome vasomotor symptoms is generally favourable — and that risk rises with later initiation and with age. Route matters too: transdermal estradiol avoids the first-pass liver effect and is associated with a lower venous thromboembolism risk than oral, and micronised progesterone has a different profile from the medroxyprogesterone acetate used in the WHI.
None of this tells you what you should take. That is genuinely an individual decision that depends on your symptoms, your history of breast cancer, clots, stroke, liver disease and migraine, your risk of fracture, and what you actually want — and it belongs in a conversation with your own clinician. What the evidence does say is that the 2002 headline was a poor summary of the 2002 trial, and a worse one for a 51-year-old today. If you were steered away from even discussing the option on the strength of that headline, it is reasonable to reopen the discussion. Our hormone therapy page goes into the formulations and contraindications in more detail.
What else actually works
Plenty of women cannot take estrogen, or do not want to. The non-hormonal evidence base is real, and it is more honest than the supplement aisle suggests.
With reasonable evidence for vasomotor symptoms: cognitive behavioural therapy and clinical hypnosis, both of which reduce how bothersome flashes are and improve sleep, and neither of which gets prescribed nearly often enough; certain SSRIs and SNRIs, with low-dose paroxetine being the one specifically approved for this indication — though it must be avoided in women taking tamoxifen, because it inhibits the enzyme that activates it; gabapentin, which is particularly useful when the main problem is night sweats; oxybutynin; fezolinetant and the NK3-antagonist class described above; and weight loss where relevant. For bone, resistance and impact exercise, adequate protein, and adequate vitamin D and calcium intake support the skeleton, with prescription antiresorptive drugs available when fracture risk is high.
Where the evidence is weaker than the marketing: black cohosh is the most-studied herbal option and the trial results are genuinely mixed, with several well-conducted randomised trials showing no advantage over placebo; soy isoflavones show small and inconsistent effects that may depend on whether an individual’s gut bacteria can produce equol; sage and maca have some encouraging small studies but not the trial weight to be called established. We list these because women ask about them and deserve a straight answer, not because they are equivalent to the options above. Compounded “bioidentical” hormone pellets and creams, by contrast, are worth avoiding: they are unregulated, inconsistently dosed, and offer nothing that regulated body-identical estradiol and micronised progesterone do not.
And the unglamorous ones do count: layered clothing, a cool bedroom, limiting alcohol and hot drinks in the evening, and not smoking — smoking both worsens hot flashes and brings menopause forward by roughly a year or two.